Executive Summary

Oct 2019
PROSPECTS
Analgesics continues growing against a backdrop of innovation and dengue

Colombia’s Ministry of Health of Colombia sounded an official warning about the possible outbreak of a dengue epidemic in the country in early 2019. National Institute of Health estimates said the possible number of cases could reach 120,000 over the course of 2019, compared with previous epidemics in 2016 (101,016 recorded cases), in 2013 (125,554) and in 2010 (156,977).

Analgesics among the worst-affected consumer health products by illegal sales

Analgesics is one of the products with the highest rates of illegal sales in the country, according to INVIMA (National Institute of Food and Drug Surveillance). INVIMA said that it has eliminated more than 9,000 e-commerce platforms selling illegal pharmaceutical products.

Aspirin no longer recommended to prevent heart attacks in healthy adults

A daily dose of aspirin is no longer recommended as a preventative for healthy people after research and studies showed that the health risks might outweigh the benefits. With aspirin associated with possibly causing bleeding or even haemorrhaging, the thinking is now that it should not be given to older adults who do not have a high risk of or existing heart disease.

COMPETITIVE LANDSCAPE
Chalver launches new Multidol 400mg (OTC) and 800mg (Rx) products

When launching its new Multidol brand Chalver de Colombia made sure that it met the new regulations laid down by INVIMA. The law on this type of medication defines a limit of milligrams for each pill for it to be considered OTC or RX.

Branded products preferred despite attractive prices of generics

Analgesics under well-known brands are still likely to be preferred by consumers in Colombia as well as more likely to be recommended by pharmacists than generics, even though generic drugs have the same effectiveness as branded products and can be significantly cheaper.

Foreign players lead analgesics, with GSK Consumer Healthcare in a very strong position

Foreign players maintained the leading positions in analgesics in Colombia in 2019, with leading player GSK Consumer Healthcare alone accounting for almost half of total retail value sales, thanks mainly to its popular Dolex and Advil brands. Advil was still under Pfizer as its NBO and GBO until last year, but is now under GSK, following the two companies’ merging of their consumer healthcare businesses.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Analgesics in Colombia

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Colombia with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Colombia, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Colombia market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in Colombia?
  • What are the major brands in Colombia?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in Colombia - Category analysis

HEADLINES

PROSPECTS

Analgesics continues growing against a backdrop of innovation and dengue
Analgesics among the worst-affected consumer health products by illegal sales
Aspirin no longer recommended to prevent heart attacks in healthy adults

COMPETITIVE LANDSCAPE

Chalver launches new Multidol 400mg (OTC) and 800mg (Rx) products
Branded products preferred despite attractive prices of generics
Foreign players lead analgesics, with GSK Consumer Healthcare in a very strong position

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in Colombia - Industry Overview

EXECUTIVE SUMMARY

Consumer health continues to grow in 2019
Smuggling remains a problem for the consumer health market in Colombia
GSK Consumer Healthcare the clear leader, with foreign companies leading most categories
Chemists/pharmacies still the leading distribution channel
Increasing awareness of self-care and an ageing population will help drive sales

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2018-2019

DEFINITIONS

SOURCES

Summary 2 Research Sources